Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Proceedings of the National Academy of Sciences of the United States of America - 27 Mar 2012

Neff Tobias, Sinha Amit U, Kluk Michael J, Zhu Nan, Khattab Mohamed H, Stein Lauren, Xie Huafeng, Orkin Stuart H, Armstrong Scott A

Abstract excerpt

A growing body of data suggests the importance of epigenetic mechanisms in cancer. Polycomb repressive complex 2 (PRC2) has been implicated in self-renewal and cancer progression, and its components are overexpressed in many cancers. However, its role in cancer development and progression remains unclear. We used conditional alleles for the PRC2 components enhancer of zeste 2 (Ezh2) and embryonic ectoderm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin Immunoprecipitation
Share to Cytoprotection

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Gene Expression Regulation, Leukemic

Share to Genes, Neoplasm

Share to Polycomb-Group Proteins

Share to Polycomb Repressive Complex 2

Share to Proto-Oncogene Proteins c-myc

Source

Open in PubMed Open full text

Identifiers

PMID: 22396593
DOI: 10.1073/pnas.1202258109
PMCID: PMC3324004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.PMID 22396593Read ↗

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemiaSemantic proximity Read ↗

Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2Semantic proximity Read ↗

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.Semantic proximity Read ↗

The epigenetic role of EZH2 in acute myeloid leukemiaSemantic proximity Read ↗

Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

The role of EZH2 in the induction and maintenance of acute myeloid leukaemiaSemantic proximity Read ↗

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemiaSemantic proximity Read ↗

EZH2 in Myeloid Malignancies.Semantic proximity Read ↗

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.Semantic proximity Read ↗

Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphomaSemantic proximity Read ↗

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLSemantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.